KLRA vs VKTX
KLRA: Kailera Therapeutics is a clinical-stage biotechnology company advancing a diversified pipeline of GLP-1-based therapies for the treatment of obesity. VKTX: A clinical-stage biopharmaceutical company developing next-generation dual GLP-1/GIP receptor agonists for the treatment of obesity and metabolic disorders.
Side-by-side fundamentals
| Metric | KLRA | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-10-22 close | $13.27 | $25.83 | |
| Market cap | $1.7B | $3.0B | |
| ROE FY2025, SEC XBRL | n/a | -56.3% | |
| ROA FY2025, SEC XBRL | n/a | -50.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 2.14 | 1.50 | |
| 1-year return as of 2026-10-22 close | n/a | -17.8% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.